Sclerosis multiplex (SM): vizsgálatok itt: Brazília
5 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- Where
- Brasília, Curitiba, Porto Alegre, São Paulo
- Életkor
- 10 év to 17 év
- People
- 12 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07161258 · EU 2024-519800-28-00 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Fortaleza, Joinville, Porto Alegre, São Paulo
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Fortaleza, Joinville, Porto Alegre, Rio de Janeiro, Santo André, São Paulo
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Brasília, Curitiba, Joinville
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- São Paulo
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00